Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management
/PRNewswire/ According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus.
/PRNewswire/ With the approvals of GlaxoSmithKline s Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia s Lupkynis (voclosporin) at.
/PRNewswire/ Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the.
/PRNewswire/ With the approvals of GlaxoSmithKline s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia s Lupkynis at the beginning of 2021,.
3 Favorite Names With Exciting Potential I m looking for some trades as these names bounce around. Stocks quotes in this article: AUPH, POWW, ENGMF The market is trading mixed Monday, but I see some productive action in individual stocks I ve recently discussed. I m looking for some trades as these names bounce around. Aurinia Pharmaceuticals (AUPH) I discussed my short-term buy of AUPH on March 11. This morning news was released. There was a favorable assessment regarding the cost-effectiveness and value of Aurinia s Lupkynis by the Institute for Clinical and Economic Review in a revised Evidence Report issued on March 12. The report finds that Lupkynis represents an important new treatment option for patients living with lupus nephritis and at the estimated net price, determined the therapy to be priced in alignment with ICER s recommended health-benefit price benchmark ranges.
/PRNewswire/ The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As.